Mediates E3-dependent ubiquitination and proteasomal degradation of target proteins, including p53/TP53, HDAC1 and p27Kip1. Preferentially acts on tetrameric p53/TP53. Contributes to the regulation of p27Kip1 and p53/TP53 levels, and thereby contributes to the regulation of the cell cycle progression. Increases AR transcription factor activity. Monomer and homodimer. Interacts with AR, p53/TP53, MDM2, HDAC1, KAT5, PLAG1, PLAGL2, p27Kip1, COPE, UBE2D2 and GORAB/NTKLBP1. Up-regulated during the S phase of the cell cycle. Expressed at low levels during G phase. 3 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.
Protein type: EC 6.3.2.-; EC 220.127.116.11; Ubiquitin ligase; Nuclear receptor co-regulator; Ubiquitin conjugating system
Molecular Function: protein binding; protein homodimerization activity; zinc ion binding; p53 binding; ubiquitin-protein ligase activity; ligase activity; receptor binding
Biological Process: protein autoubiquitination; positive regulation of protein ubiquitination; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; protein ubiquitination during ubiquitin-dependent protein catabolic process; protein ubiquitination
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.